TaƱeza, Jonalyn S.
HRN: 22-17-39 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/09/2022
CEFUROXIME 500MG (TAB)
11/09/2022
11/16/2022
PO
500mg
Q12
S/P Pelvic Laparotomy
Waiting Final Action
Indication: Empirical De-escalation Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes